Username

Password

Forgot Password?

Preview

Sign-in free and Explore the Exciting World of BiomedExperts:

Over 1.500.000 Profiles
More than 1.800 Organizations worldwide
State of the Art Network Visualizations

Manage your own Profile
Locate Experts in your Country/Region
Locate Experts in your 1. and 2. Level Network
Connect to Experts Worldwide

NetworkView

Gary Tollefson

This is a preview profile on BiomedExperts - the first literature-based scientific social network. It brings the right researchers together and allows them to collaborate online. Collexis and Dell provide the BiomedExperts network of +1.5 Million pre-calculated profiles free of charge to researchers worldwide.

Research Profile (preview)

Chemicals & Drugs

Procedures

Concepts & Ideas

Disorders

Activities & Behaviors

Schizophrenic Psychology

Devices

Placebos

Sign-in to see full Profile

Network (preview)

Co-Publications
Name
15
Sanger, Todd
15
Beasley, Charles
13
Tohen, Mauricio
12
Tran, Pierre
8
Breier, Alan
6
Bymaster, Frank
6
Dellva, MA
6
Tamura, Roy
5
Hamilton, Susan
5
Kinon, Bruce
4
Gilmore, Julie
4
Andersen, Scott
4
Dossenbach, Martin
4
Risser, Richard
4
Feldman, Peter

Sign-in to see all Coauthors

Publications

TOP 3
Dubé Sanjay; Tollefson Gary D; Thase Michael E; Briggs Susan D; Van Campen Luann E; Case Michael; Tohen Mauricio
Onset of antidepressant effect of olanzapine and olanzapine/fluoxetine combination in bipolar depression.
Nierenberg Andrew A; Greist John H; Mallinckrodt Craig H; Prakash Apurva; Sambunaris Angelo; Tollefson Gary D; Wohlreich Madelaine M
Duloxetine versus escitalopram and placebo in the treatment of patients with major depressive disorder: onset of antidepressant action, a non-inferiority study.
Keefe Richard S E; Seidman Larry J; Christensen Bruce K; Hamer Robert M; Sharma Tonmoy; Sitskoorn Margriet M; Rock Stephanie L; Woolson Sandra; Tohen Mauricio; Tollefson Gary D; Sanger Todd M; Lieberman Jeffrey A;
Long-term neurocognitive effects of olanzapine or low-dose haloperidol in first-episode psychosis.

Sign-in to see all Publications

Sign in free and see...

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the visualized research activity
of experts around the globe

Sign-in to see more

Geonetwork of Gary Tollefson (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

Sign-in to see more

All Publications

2007: Dubé Sanjay; Tollefson Gary D; Thase Michael E; Briggs Susan D; Van Campen Luann E; Case Michael; Tohen Mauricio
Onset of antidepressant effect of olanzapine and olanzapine/fluoxetine combination in bipolar depression.
Bipolar disorders 2007;9(6):618-27.
2007: Nierenberg Andrew A; Greist John H; Mallinckrodt Craig H; Prakash Apurva; Sambunaris Angelo; Tollefson Gary D; Wohlreich Madelaine M
Duloxetine versus escitalopram and placebo in the treatment of patients with major depressive disorder: onset of antidepressant action, a non-inferiority study.
Current medical research and opinion 2007;23(2):401-16.
2006: Keefe Richard S E; Seidman Larry J; Christensen Bruce K; Hamer Robert M; Sharma Tonmoy; Sitskoorn Margriet M; Rock Stephanie L; Woolson Sandra; Tohen Mauricio; Tollefson Gary D; Sanger Todd M; Lieberman Jeffrey A;
Long-term neurocognitive effects of olanzapine or low-dose haloperidol in first-episode psychosis.
Biological psychiatry 2006;59(2):97-105.
2006: Corya Sara A; Williamson Doug; Sanger Todd M; Briggs Susan D; Case Michael; Tollefson Gary
A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, fluoxetine, and venlafaxine in treatment-resistant depression.
Depression and anxiety 2006;23(6):364-72.
2005: Zipursky Robert B; Gu Hongbin; Green Alan I; Perkins Diana O; Tohen Mauricio F; McEvoy Joseph P; Strakowski Stephen M; Sharma Tonmoy; Kahn René S; Gur Raquel E; Tollefson Gary D; Lieberman Jeffrey A
Course and predictors of weight gain in people with first-episode psychosis treated with olanzapine or haloperidol.
The British journal of psychiatry : the journal of mental science 2005;187():537-43.
2005: Ascher-Svanum Haya; Stensland Michael D; Kinon Bruce J; Tollefson Gary D
Weight gain as a prognostic indicator of therapeutic improvement during acute treatment of schizophrenia with placebo or active antipsychotic.
Journal of psychopharmacology (Oxford, England) 2005;19(6 Suppl):110-7.
2005: Shelton Richard C; Williamson Douglas J; Corya Sara A; Sanger Todd M; Van Campen Luann E; Case Michael; Briggs Susan D; Tollefson Gary D
Olanzapine/fluoxetine combination for treatment-resistant depression: a controlled study of SSRI and nortriptyline resistance.
The Journal of clinical psychiatry 2005;66(10):1289-97.
2005: Brannan Stephen K; Mallinckrodt Craig H; Detke Michael J; Watkin John G; Tollefson Gary D
Onset of action for duloxetine 60 mg once daily: double-blind, placebo-controlled studies.
Journal of psychiatric research 2005;39(2):161-72.
2004: Rothschild Anthony J; Williamson Douglas J; Tohen Mauricio F; Schatzberg Alan; Andersen Scott W; Van Campen Luann E; Sanger Todd M; Tollefson Gary D
A double-blind, randomized study of olanzapine and olanzapine/fluoxetine combination for major depression with psychotic features.
Journal of clinical psychopharmacology 2004;24(4):365-73.
2004: Keefe Richard S E; Seidman Larry J; Christensen Bruce K; Hamer Robert M; Sharma Tonmoy; Sitskoorn Margriet M; Lewine Richard R J; Yurgelun-Todd Deborah A; Gur Ruben C; Tohen Mauricio; Tollefson Gary D; Sanger Todd M; Lieberman Jeffrey A
Comparative effect of atypical and conventional antipsychotic drugs on neurocognition in first-episode psychosis: a randomized, double-blind trial of olanzapine versus low doses of haloperidol.
The American journal of psychiatry 2004;161(6):985-95.
2004: Dossenbach Martin R K; Folnegovic-Smalc Vera; Hotujac Ljubomir; Uglesic Borben; Tollefson Gary D; Grundy Starr L; Friedel Philip; Jakovljevic Miroslav Miro;
Double-blind, randomized comparison of olanzapine versus fluphenazine in the long-term treatment of schizophrenia.
Progress in neuro-psychopharmacology & biological psychiatry 2004;28(2):311-8.
2003: Beasley Charles M; Sutton Virginia K; Hamilton Susan H; Walker Daniel J; Dossenbach Martin; Taylor Cindy C; Alaka Karla J; Bykowski Deborah; Tollefson Gary D;
A double-blind, randomized, placebo-controlled trial of olanzapine in the prevention of psychotic relapse.
Journal of clinical psychopharmacology 2003;23(6):582-94.
2003: Kennedy J S; Jeste D; Kaiser C J; Golshan S; Maguire G A; Tollefson G; Sanger T; Bymaster F P; Kinon B J; Dossenbach M; Gilmore J A; Breier A
Olanzapine vs haloperidol in geriatric schizophrenia: analysis of data from a double-blind controlled trial.
International journal of geriatric psychiatry 2003;18(11):1013-20.
2003: Tohen Mauricio; Vieta Eduard; Calabrese Joseph; Ketter Terence A; Sachs Gary; Bowden Charles; Mitchell Philip B; Centorrino Franca; Risser Richard; Baker Robert W; Evans Angela R; Beymer Karin; Dube Sanjay; Tollefson Gary D; Breier Alan
Efficacy of olanzapine and olanzapine-fluoxetine combination in the treatment of bipolar I depression.
Archives of general psychiatry 2003;60(11):1079-88.
2003: Feldman Peter D; Kaiser Christopher J; Kennedy John S; Sutton Virginia K; Tran Pierre V; Tollefson Gary D; Zhang Fan; Breier Alan
Comparison of risperidone and olanzapine in the control of negative symptoms of chronic schizophrenia and related psychotic disorders in patients aged 50 to 65 years.
The Journal of clinical psychiatry 2003;64(9):998-1004.
2003: Mallinckrodt Craig H; Sanger Todd M; Dubé Sanjay; DeBrota David J; Molenberghs Geert; Carroll Raymond J; Potter William Z; Tollefson Gary D
Assessing and interpreting treatment effects in longitudinal clinical trials with missing data.
Biological psychiatry 2003;53(8):754-60.
2003: Baker Robert W; Tohen Mauricio; Fawcett Jan; Risser Richard C; Schuh Leslie M; Brown Eileen; Stauffer Virginia L; Shao Lixin; Tollefson Gary D
Acute dysphoric mania: treatment response to olanzapine versus placebo.
Journal of clinical psychopharmacology 2003;23(2):132-7.
2002: Tohen Mauricio; Chengappa K N Roy; Suppes Trisha; Zarate Carlos A; Calabrese Joseph R; Bowden Charles L; Sachs Gary S; Kupfer David J; Baker Robert W; Risser Richard C; Keeter Elisabeth L; Feldman Peter D; Tollefson Gary D; Breier Alan
Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to valproate or lithium monotherapy.
Archives of general psychiatry 2002;59(1):62-9.
2001: Faries D E; Heiligenstein J H; Tollefson G D; Potter W Z
The double-blind variable placebo lead-in period: results from two antidepressant clinical trials.
Journal of clinical psychopharmacology 2001;21(6):561-8.
2001: Kennedy J S; Zagar A; Bymaster F; Nomikos G; Trzepacz P T; Gilmore J A; Rotelli M D; Breier A; Tollefson G
The central cholinergic system profile of olanzapine compared with placebo in Alzheimer's disease.
International journal of geriatric psychiatry 2001;16 Suppl 1():S24-32.
2001: Tohen M; Zhang F; Taylor C C; Burns P; Zarate C; Sanger T; Tollefson G
A meta-analysis of the use of typical antipsychotic agents in bipolar disorder.
Journal of affective disorders 2001;65(1):85-93.
2001: Basson B R; Kinon B J; Taylor C C; Szymanski K A; Gilmore J A; Tollefson G D
Factors influencing acute weight change in patients with schizophrenia treated with olanzapine, haloperidol, or risperidone.
The Journal of clinical psychiatry 2001;62(4):231-8.
2001: Kinon B J; Basson B R; Gilmore J A; Tollefson G D
Long-term olanzapine treatment: weight change and weight-related health factors in schizophrenia.
The Journal of clinical psychiatry 2001;62(2):92-100.
2001: Casper R C; Tollefson G D; Nilsson M E
No gender differences in placebo responses of patients with major depressive disorder.
Biological psychiatry 2001;49(2):158-60.
2001: Tollefson G D; Birkett M A; Kiesler G M; Wood A J;
Double-blind comparison of olanzapine versus clozapine in schizophrenic patients clinically eligible for treatment with clozapine.
Biological psychiatry 2001;49(1):52-63.
2001: Shelton R C; Tollefson G D; Tohen M; Stahl S; Gannon K S; Jacobs T G; Buras W R; Bymaster F P; Zhang W; Spencer K A; Feldman P D; Meltzer H Y
A novel augmentation strategy for treating resistant major depression.
The American journal of psychiatry 2001;158(1):131-4.
2001: Dossenbach M R; Kratky P; Schneidman M; Grundy S L; Metcalfe S; Tollefson G D; Belmaker R H
Evidence for the effectiveness of olanzapine among patients nonresponsive and/or intolerant to risperidone.
The Journal of clinical psychiatry 2001;62 Suppl 2():28-34.
2000: Street J S; Clark W S; Gannon K S; Cummings J L; Bymaster F P; Tamura R N; Mitan S J; Kadam D L; Sanger T M; Feldman P D; Tollefson G D; Breier A
Olanzapine treatment of psychotic and behavioral symptoms in patients with Alzheimer disease in nursing care facilities: a double-blind, randomized, placebo-controlled trial. The HGEU Study Group.
Archives of general psychiatry 2000;57(10):968-76.
2000: Dossenbach MRK; Beuzen J N; Avnon M; Belmaker R H; Elizur A; Mark M; Munitz H; Schneidman M; Shoshani D; Kratky P; Grundy S L; Tollefson G D
The effectiveness of olanzapine in treatment-refractory schizophrenia when patients are nonresponsive to or unable to tolerate clozapine.
Clinical therapeutics 2000;22(9):1021-34.
2000: Tohen M; Jacobs T G; Grundy S L; McElroy S L; Banov M C; Janicak P G; Sanger T; Risser R; Zhang F; Toma V; Francis J; Tollefson G D; Breier A
Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. The Olanzipine HGGW Study Group.
Archives of general psychiatry 2000;57(9):841-9.
2000: Zhang W; Perry K W; Wong D T; Potts B D; Bao J; Tollefson G D; Bymaster F P
Synergistic effects of olanzapine and other antipsychotic agents in combination with fluoxetine on norepinephrine and dopamine release in rat prefrontal cortex.
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 2000;23(3):250-62.
2000: Bech P; Cialdella P; Haugh M C; Birkett M A; Hours A; Boissel J P; Tollefson G D
Meta-analysis of randomised controlled trials of fluoxetine v. placebo and tricyclic antidepressants in the short-term treatment of major depression.
The British journal of psychiatry : the journal of mental science 2000;176():421-8.
2000: Poyurovsky M; Dorfman-Etrog P; Hermesh H; Munitz H; Tollefson G D; Weizman A
Beneficial effect of olanzapine in schizophrenic patients with obsessive-compulsive symptoms.
International clinical psychopharmacology 2000;15(3):169-73.
2000: Purdon S E; Jones B D; Stip E; Labelle A; Addington D; David S R; Breier A; Tollefson G D
Neuropsychological change in early phase schizophrenia during 12 months of treatment with olanzapine, risperidone, or haloperidol. The Canadian Collaborative Group for research in schizophrenia.
Archives of general psychiatry 2000;57(3):249-58.
1999: Tollefson G D; Dellva M A; Mattler C A; Kane J M; Wirshing D A; Kinon B J
Controlled, double-blind investigation of the clozapine discontinuation symptoms with conversion to either olanzapine or placebo. The Collaborative Crossover Study Group.
Journal of clinical psychopharmacology 1999;19(5):435-43.
1999: Tollefson G D; Andersen S W; Tran P V
The course of depressive symptoms in predicting relapse in schizophrenia: a double-blind, randomized comparison of olanzapine and risperidone.
Biological psychiatry 1999;46(3):365-73.
1999: Hamilton S H; Revicki D A; Edgell E T; Genduso L A; Tollefson G
Clinical and economic outcomes of olanzapine compared with haloperidol for schizophrenia. Results from a randomised clinical trial.
PharmacoEconomics 1999;15(5):469-80.
1999: Tohen M; Sanger T M; McElroy S L; Tollefson G D; Chengappa K N; Daniel D G; Petty F; Centorrino F; Wang R; Grundy S L; Greaney M G; Jacobs T G; David S R; Toma V
Olanzapine versus placebo in the treatment of acute mania. Olanzapine HGEH Study Group.
The American journal of psychiatry 1999;156(5):702-9.
1999: Michelson D; Pollack M; Lydiard R B; Tamura R; Tepner R; Tollefson G
Continuing treatment of panic disorder after acute response: randomised, placebo-controlled trial with fluoxetine. The Fluoxetine Panic Disorder Study Group.
The British journal of psychiatry : the journal of mental science 1999;174():213-8.
1999: Tollefson G D; Sanger T M
Anxious-depressive symptoms in schizophrenia: a new treatment target for pharmacotherapy?
Schizophrenia research 1999;35 Suppl():S13-21.
1999: Beasley C M; Dellva M A; Tamura R N; Morgenstern H; Glazer W M; Ferguson K; Tollefson G D
Randomised double-blind comparison of the incidence of tardive dyskinesia in patients with schizophrenia during long-term treatment with olanzapine or haloperidol.
The British journal of psychiatry : the journal of mental science 1999;174():23-30.
1999: Tran P V; Tollefson G D; Sanger T M; Lu Y; Berg P H; Beasley C M
Olanzapine versus haloperidol in the treatment of schizoaffective disorder. Acute and long-term therapy.
The British journal of psychiatry : the journal of mental science 1999;174():15-22.
1999: Sanger T M; Lieberman J A; Tohen M; Grundy S; Beasley C; Tollefson G D
Olanzapine versus haloperidol treatment in first-episode psychosis.
The American journal of psychiatry 1999;156(1):79-87.
1999: Tollefson G D; Kuntz A J
Review of recent clinical studies with olanzapine.
The British journal of psychiatry. Supplement 1999;(37):30-5.
1999: Tollefson G D; Andersen S W
Should we consider mood disturbance in schizophrenia as an important determinant of quality of life?
The Journal of clinical psychiatry 1999;60 Suppl 5():23-9; discussion 30.
1998: Michelson D; Lydiard R B; Pollack M H; Tamura R N; Hoog S L; Tepner R; Demitrack M A; Tollefson G D
Outcome assessment and clinical improvement in panic disorder: evidence from a randomized controlled trial of fluoxetine and placebo. The Fluoxetine Panic Disorder Study Group.
The American journal of psychiatry 1998;155(11):1570-7.
1998: Tran P V; Dellva M A; Tollefson G D; Wentley A L; Beasley C M
Oral olanzapine versus oral haloperidol in the maintenance treatment of schizophrenia and related psychoses.
The British journal of psychiatry : the journal of mental science 1998;172():499-505.
1998: Tollefson G D; Sanger T M; Beasley C M; Tran P V
A double-blind, controlled comparison of the novel antipsychotic olanzapine versus haloperidol or placebo on anxious and depressive symptoms accompanying schizophrenia.
Biological psychiatry 1998;43(11):803-10.
1998: Tollefson G D; Sanger T M; Lu Y; Thieme M E
Depressive signs and symptoms in schizophrenia: a prospective blinded trial of olanzapine and haloperidol.
Archives of general psychiatry 1998;55(3):250-8.
1998: Hylan T R; Buesching D P; Tollefson G D
Health economic evaluations of antidepressants: a review.
Depression and anxiety 1998;7(2):53-64.
1997: Dellva M A; Tran P; Tollefson G D; Wentley A L; Beasley C M
Standard olanzapine versus placebo and ineffective-dose olanzapine in the maintenance treatment of schizophrenia.
Psychiatric services (Washington, D.C.) 1997;48(12):1571-7.
1997: Tran P V; Hamilton S H; Kuntz A J; Potvin J H; Andersen S W; Beasley C; Tollefson G D
Double-blind comparison of olanzapine versus risperidone in the treatment of schizophrenia and other psychotic disorders.
Journal of clinical psychopharmacology 1997;17(5):407-18.
1997: Tollefson G D; Beasley C M; Tamura R N; Tran P V; Potvin J H
Blind, controlled, long-term study of the comparative incidence of treatment-emergent tardive dyskinesia with olanzapine or haloperidol.
The American journal of psychiatry 1997;154(9):1248-54.
1997: Crawford A M; Beasley C M; Tollefson G D
The acute and long-term effect of olanzapine compared with placebo and haloperidol on serum prolactin concentrations.
Schizophrenia research 1997;26(1):41-54.
1997: Tran P V; Dellva M A; Tollefson G D; Beasley C M; Potvin J H; Kiesler G M
Extrapyramidal symptoms and tolerability of olanzapine versus haloperidol in the acute treatment of schizophrenia.
The Journal of clinical psychiatry 1997;58(5):205-11.
1997: Beasley C M; Hamilton S H; Crawford A M; Dellva M A; Tollefson G D; Tran P V; Blin O; Beuzen J N
Olanzapine versus haloperidol: acute phase results of the international double-blind olanzapine trial.
European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology 1997;7(2):125-37.
1997: Bodick N C; Offen W W; Levey A I; Cutler N R; Gauthier S G; Satlin A; Shannon H E; Tollefson G D; Rasmussen K; Bymaster F P; Hurley D J; Potter W Z; Paul S M
Effects of xanomeline, a selective muscarinic receptor agonist, on cognitive function and behavioral symptoms in Alzheimer disease.
Archives of neurology 1997;54(4):465-73.
1997: Tollefson G D; Sanger T M
Negative symptoms: a path analytic approach to a double-blind, placebo- and haloperidol-controlled clinical trial with olanzapine.
The American journal of psychiatry 1997;154(4):466-74.
1997: Tollefson G D; Beasley C M; Tran P V; Street J S; Krueger J A; Tamura R N; Graffeo K A; Thieme M E
Olanzapine versus haloperidol in the treatment of schizophrenia and schizoaffective and schizophreniform disorders: results of an international collaborative trial.
The American journal of psychiatry 1997;154(4):457-65.
1997: Wernicke J F; Sayler M E; Koke S C; Pearson D K; Tollefson G D
Fluoxetine and concomitant centrally acting medication use during clinical trials of depression: the absence of an effect related to agitation and suicidal behavior.
Depression and anxiety 1997;6(1):31-9.
1997: Beasley C M; Tollefson G D; Tran P V
Safety of olanzapine.
The Journal of clinical psychiatry 1997;58 Suppl 10():13-7.
1997: Beasley C M; Tollefson G D; Tran P V
Efficacy of olanzapine: an overview of pivotal clinical trials.
The Journal of clinical psychiatry 1997;58 Suppl 10():7-12.
1996: Tollefson G D; Heiligenstein J H; Tollefson S L; Birkett M A; Knight D L; Nemeroff C B
Is there a relationship between baseline and treatment-associated changes in [3H]-IMI platelet binding and clinical response in major depression?
Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 1996;14(1):47-53.
1996: Tollefson G D; Sayler M E
Course of psychomotor agitation during pharmacotherapy of depression: analysis from double-blind controlled trials with fluoxetine.
Depression and anxiety 1996;4(6):294-311.
1996: Tollefson G D
Cognitive function in schizophrenic patients.
The Journal of clinical psychiatry 1996;57 Suppl 11():31-9.
1995: Koran L M; Hamilton S H; Hertzman M; Meyers B S; Halaris A E; Tollefson G D; Downs J M; Folks D G; Jeste D V; Lazarus L W
Predicting response to fluoxetine in geriatric patients with major depression.
Journal of clinical psychopharmacology 1995;15(6):421-7.
1995: Heiligenstein J H; Ware J E; Beusterien K M; Roback P J; Andrejasich C; Tollefson G D
Acute effects of fluoxetine versus placebo on functional health and well-being in late-life depression.
International psychogeriatrics / IPA 1995;7 Suppl():125-37.
1995: Tollefson G D; Bosomworth J C; Heiligenstein J H; Potvin J H; Holman S
A double-blind, placebo-controlled clinical trial of fluoxetine in geriatric patients with major depression. The Fluoxetine Collaborative Study Group.
International psychogeriatrics / IPA 1995;7(1):89-104.
1994: Tollefson G D; Greist J H; Jefferson J W; Heiligenstein J H; Sayler M E; Tollefson S L; Koback K
Is baseline agitation a relative contraindication for a selective serotonin reuptake inhibitor: a comparative trial of fluoxetine versus imipramine.
Journal of clinical psychopharmacology 1994;14(6):385-91.
1994: Tollefson G D; Birkett M; Koran L; Genduso L
Continuation treatment of OCD: double-blind and open-label experience with fluoxetine.
The Journal of clinical psychiatry 1994;55 Suppl():69-76; discussion 77-8.
1994: Tollefson G D; Rampey A H; Potvin J H; Jenike M A; Rush A J; kominguez R A; Koran L M; Shear M K; Goodman W; Genduso L A
A multicenter investigation of fixed-dose fluoxetine in the treatment of obsessive-compulsive disorder.
Archives of general psychiatry 1994;51(7):559-67.
1994: Tollefson G D; Rampey A H; Beasley C M; Enas G G; Potvin J H
Absence of a relationship between adverse events and suicidality during pharmacotherapy for depression.
Journal of clinical psychopharmacology 1994;14(3):163-9.
1994: Heiligenstein J H; Tollefson G D; Faries D E
Response patterns of depressed outpatients with and without melancholia: a double-blind, placebo-controlled trial of fluoxetine versus placebo.
Journal of affective disorders 1994;30(3):163-73.
1994: Tollefson G D; Holman S L; Sayler M E; Potvin J H
Fluoxetine, placebo, and tricyclic antidepressants in major depression with and without anxious features.
The Journal of clinical psychiatry 1994;55(2):50-9.
1994: Tollefson G D; Holman S L
How long to onset of antidepressant action: a meta-analysis of patients treated with fluoxetine or placebo.
International clinical psychopharmacology 1994;9(4):245-50.
1993: Tollefson G D; Fawcett J; Winokur G; Beasley C M; Potvin J H; Faries D E; Rampey A H; Sayler M E
Evaluation of suicidality during pharmacologic treatment of mood and nonmood disorders.
Annals of clinical psychiatry : official journal of the American Academy of Clinical Psychiatrists 1993;5(4):209-24.
1993: Tollefson G D
Adverse drug reactions/interactions in maintenance therapy.
The Journal of clinical psychiatry 1993;54 Suppl():48-58; discussion 59-60.
1993: Wood A; Tollefson G D; Birkett M
Pharmacotherapy of obsessive compulsive disorder--experience with fluoxetine.
International clinical psychopharmacology 1993;8(4):301-6.
1993: Tollefson G D; Souetre E; Thomander L; Potvin J H
Comorbid anxious signs and symptoms in major depression: impact on functional work capacity and comparative treatment outcomes.
International clinical psychopharmacology 1993;8(4):281-93.
1993: Tollefson G D; Holman S L
Analysis of the Hamilton Depression Rating Scale factors from a double-blind, placebo-controlled trial of fluoxetine in geriatric major depression.
International clinical psychopharmacology 1993;8(4):253-9.
1993: Heiligenstein J H; Tollefson G D; Faries D E
A double-blind trial of fluoxetine, 20 mg, and placebo in out-patients with DSM-III-R major depression and melancholia.
International clinical psychopharmacology 1993;8(4):247-51.
1992: Tollefson G D; Montague-Clouse J; Tollefson S L
Treatment of comorbid generalized anxiety in a recently detoxified alcoholic population with a selective serotonergic drug (buspirone).
Journal of clinical psychopharmacology 1992;12(1):19-26.
1991: Tollefson G D; Luxenberg M; Valentine R; Dunsmore G; Tollefson S L
An open label trial of alprazolam in comorbid irritable bowel syndrome and generalized anxiety disorder.
The Journal of clinical psychiatry 1991;52(12):502-8.
1991: Tollefson G D
Antidepressant treatment and side effect considerations.
The Journal of clinical psychiatry 1991;52 Suppl():4-13.
1991: Tollefson G D; Lancaster S P; Montague-Clouse J
The association of buspirone and its metabolite 1-pyrimidinylpiperazine in the remission of comorbid anxiety with depressive features and alcohol dependency.
Psychopharmacology bulletin 1991;27(2):163-70.
1991: Tollefson G D; Montague-Clouse J; Lancaster S P
The relationship of serum anticholinergic activity to mental status performance in an elderly nursing home population.
The Journal of neuropsychiatry and clinical neurosciences 1991;3(3):314-9.
1989: Tollefson G D; Montague-Clouse J; Lesan T; Garvey M J
Pharmacokinetic properties of maprotiline in geriatric depression.
Journal of clinical psychopharmacology 1989;9(4):313-5.
1989: Tollefson G D; Godes M; Montague-Clouse J; Lancaster S P; Garvey M J
Buspirone: effects on prolactin and growth hormone as a function of drug level in generalized anxiety.
Journal of clinical psychopharmacology 1989;9(2):132-6.
1989: Tollefson G D; Godes M; Warren J B; Haus E; Luxenberg M; Garvey M
Lymphopenia in primary degenerative dementia.
Journal of psychiatric research 1989;23(3-4):191-9.
1988: Tollefson G D; Montague-Clouse J
Alprazolam plus buspirone in treatment of anxiety.
The American journal of psychiatry 1988;145(3):379-80.
1986: Tollefson G D; Zander J; Luxenberg M; Saxena S; Godes M; Garvey M J
Prediction of postdexamethasone cortisol levels by serum sodium levels in patients with major depression.
The American journal of psychiatry 1986;143(1):81-4.

Sign-in to see more